Keay Nakae
Stock Analyst at Chardan Capital
(4.03)
# 515
Out of 5,182 analysts
240
Total ratings
40.38%
Success rate
15.06%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANRO Alto Neuroscience | Maintains: Buy | $30 | $22.53 | +33.16% | 3 | Apr 2, 2026 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $100 | $53.68 | +86.29% | 8 | Mar 30, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $425 | $330.34 | +28.66% | 16 | Mar 25, 2026 | |
| IBIO iBio, Inc. | Maintains: Buy | $5 | $2.03 | +146.31% | 7 | Mar 18, 2026 | |
| STOK Stoke Therapeutics | Maintains: Buy | $35 | $32.79 | +6.74% | 2 | Mar 18, 2026 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $4.05 | +245.68% | 24 | Mar 16, 2026 | |
| OBIO Orchestra BioMed Holdings | Maintains: Buy | $20 | $4.24 | +372.26% | 14 | Mar 12, 2026 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $12 → $14 | $3.85 | +263.64% | 20 | Mar 11, 2026 | |
| DYN Dyne Therapeutics | Maintains: Buy | $38 | $18.35 | +107.08% | 16 | Mar 9, 2026 | |
| KRRO Korro Bio | Upgrades: Buy | $7 → $15 | $13.79 | +8.77% | 5 | Jan 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $80 | $61.12 | +30.89% | 23 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 | $0.71 | +5,517.98% | 1 | Jan 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $4.46 | +12.11% | 14 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 | $1.81 | +120.99% | 16 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 | $5.80 | +503.45% | 13 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1.25 → $6 | $8.81 | -31.90% | 10 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $1.86 | +222.58% | 7 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $0.43 | +1,761.76% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $14.87 | -59.65% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,140 → $380 | $3.07 | +12,277.85% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $8.10 | +579.01% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $4.02 | +148.76% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $26.44 | +230.94% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $1.77 | +634.46% | 3 | Feb 9, 2021 |
Alto Neuroscience
Apr 2, 2026
Maintains: Buy
Price Target: $30
Current: $22.53
Upside: +33.16%
Monopar Therapeutics
Mar 30, 2026
Maintains: Buy
Price Target: $100
Current: $53.68
Upside: +86.29%
Alnylam Pharmaceuticals
Mar 25, 2026
Maintains: Buy
Price Target: $425
Current: $330.34
Upside: +28.66%
iBio, Inc.
Mar 18, 2026
Maintains: Buy
Price Target: $5
Current: $2.03
Upside: +146.31%
Stoke Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $35
Current: $32.79
Upside: +6.74%
Coya Therapeutics
Mar 16, 2026
Maintains: Buy
Price Target: $14
Current: $4.05
Upside: +245.68%
Orchestra BioMed Holdings
Mar 12, 2026
Maintains: Buy
Price Target: $20
Current: $4.24
Upside: +372.26%
SAB Biotherapeutics
Mar 11, 2026
Maintains: Buy
Price Target: $12 → $14
Current: $3.85
Upside: +263.64%
Dyne Therapeutics
Mar 9, 2026
Maintains: Buy
Price Target: $38
Current: $18.35
Upside: +107.08%
Korro Bio
Jan 29, 2026
Upgrades: Buy
Price Target: $7 → $15
Current: $13.79
Upside: +8.77%
Jan 7, 2026
Maintains: Buy
Price Target: $60 → $80
Current: $61.12
Upside: +30.89%
Jan 5, 2026
Maintains: Buy
Price Target: $40
Current: $0.71
Upside: +5,517.98%
Nov 14, 2025
Maintains: Buy
Price Target: $5
Current: $4.46
Upside: +12.11%
Nov 4, 2025
Maintains: Buy
Price Target: $4
Current: $1.81
Upside: +120.99%
Aug 8, 2025
Maintains: Buy
Price Target: $35
Current: $5.80
Upside: +503.45%
May 8, 2025
Downgrades: Neutral
Price Target: $1.25 → $6
Current: $8.81
Upside: -31.90%
Mar 28, 2025
Maintains: Buy
Price Target: $6
Current: $1.86
Upside: +222.58%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.43
Upside: +1,761.76%
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $14.87
Upside: -59.65%
Nov 10, 2022
Maintains: Buy
Price Target: $1,140 → $380
Current: $3.07
Upside: +12,277.85%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $8.10
Upside: +579.01%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $4.02
Upside: +148.76%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $26.44
Upside: +230.94%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $1.77
Upside: +634.46%